GenomeDx Biosciences Corp. has agreed to pay $1.99 million to resolve allegations that it violated the False Claims Act by submitting false claims to Medicare for a post-operative genetic test for prostate cancer patients. The United States alleged that the company submitted claims to Medicare between September 2015 and June 2017 for the test that were not medically reasonable and necessary because the prostate cancer patients did not have risk factors necessitating the test. Read a Department of Justice press release.
SMP Resource Center products often contain links to copyrighted material. The SMP Resource Center is providing these links as a convenience and for informational purposes in our efforts to report and educate on Medicare fraud; they do not constitute a guarantee, endorsement, or approval by SMP of any of the information available on the external site. SMP bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links. If you have any questions or concerns about the links provided, please contact the SMP Center at nliebau@smpresource.org.